K. Raghupathi

发表

A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma

H. Ortega, Dave Singh, M. Fitzgerald, 2019, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.

S. Bae, D. D'cruz, D. Wallace, 2010, Arthritis and rheumatism.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

David H. Miller, M. Hutchinson, E. Havrdová, 2012, The New England journal of medicine.

The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study

S. Bae, D. D'cruz, D. Wallace, 2008 .

Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis

R. Osterhout, J. Bruey, W. Sandborn, 2022, Alimentary pharmacology & therapeutics.

Adrenal masses: characterization with combined unenhanced and delayed enhanced CT.

Melvyn Korobkin, Richard H Cohan, Elaine M Caoili, 2002, Radiology.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Jeffrey A. Cohen, D. Arnold, X. Montalban, 2019, The Lancet Neurology.

An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.

T. Pincus, M. Bergman, K. Raghupathi, 2007, Rheumatology.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Jeffrey A. Cohen, D. Arnold, X. Montalban, 2019, The Lancet Neurology.

Geomatic Approach to Assess the Flash Floods using Land Use Land Cover Maps–A case study of Kodagu district

A. Reddy, K. Raghupathi, Rajashekhar S. Laddimath, 2019 .

Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) (P3.396)

Jeffrey A. Cohen, D. Arnold, X. Montalban, 2018 .

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

M. Hutchinson, R. Gold, E. Havrdová, 2013, Expert opinion on pharmacotherapy.

Safety and Tolerability of Oral BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): Interim Results from ENDORSE Extension Study (P01.162)

R. Gold, K. Selmaj, M. Sweetser, 2013 .

Adrenal masses: characterization with combined unenhanced and delayed enhanced CT.

J. Platt, I. Francis, E. Caoili, 2002 .

Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply

R. Osterhout, J. Bruey, W. Sandborn, 2022, Alimentary pharmacology & therapeutics.